Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2025-05-10 (nzz.ch)
High losses for UBS customers in currencies
Due to the crash on the stock exchanges, investors have suffered high losses due to the obligation to make additional payments in the case of currencies. Customers of the Grossbank are particularly affected.
Read more
2024-12-25 (swissinfo.ch)
This is what Switzerland expects: Our economic outlook for 2025 -
2025 promises moderate growth for the Swiss economy, but global uncertainties and price pressure are causing tensions.
Read more
2024-11-14 (newmoney.gr)
Xavier Andre Justo (1MDB whistleblower): The identity of public interest witnesses must be protected
One of the world's most famous public interest witnesses talks to newmoney - How he exposed one of the world's biggest kleptocracy scandals - Jail, bankruptcy and years-long fight for justice - What he advises whistleblowers
Read more
2024-10-25 (ieidiseis.gr)
Pappas for Novartis: Methodology to collapse the institution of protected witnesses
"I will be in Parliament every day. What will Mitsotakis do? Will he enter and leave?" said Nikos Pappas about the departure of the Prime Minister from the Parliament.
Read more
2024-10-25 (ieidiseis.gr)
Pappas for Novartis: Methodology to collapse the institution of protected witnesses
"I will be in Parliament every day. What will Mitsotakis do? Will he enter and leave?" said Nikos Pappas about the departure of the Prime Minister from the Parliament.
Read more
2023-12-04 (propercity-frankfurt.de)
Constant demand in Munich's core locations
Even in economically weak times, new tenants were found for the top locations in Munich. This comes from the current IVD retail fluctuation study for Munich 2...
Read more
2023-01-18 (endpts.com)
Bankrupt PhaseBio settles with investor-partner, handing off late-stage drug
SFJ Pharmaceuticals is declaring the final victory in its legal tussle with PhaseBio over a blood thinner reversal agent. Backed by Abingworth and Blackstone, San Diego-based SFJ first inked a deal two years ago to provide PhaseBio with up to$ 120 million in clinical development funding in exchange
Read more
2022-12-12 (fiercepharma.com)
Clovis Oncology finally throws in the towel, files for bankruptcy
The writing has been on the wall for months, and, now, Clovis Oncology has officially thrown in the towel and filed for Chapter 11 bankruptcy protection. | After months of warnings from the company itself, Clovis Oncology has finally thrown in the towel. The company filed for Chapter 11 bankruptcy protections and sold a pipeline candidate to Novartis.
Read more
2022-07-01 (fiercepharma.com)
Novartis buys FDA priority review voucher from bankrupt Mallinckrodt for $100M
Novartis is forking over cash to speed up a future FDA drug application. | Novartis is buying a pass to expedite FDA review for a future drug application. For $100 million, the Swiss pharma is acquiring a priority review voucher from opioid crisis-crippled Mallinckrodt.
Read more
2020-08-20 (fiercepharma.com)
Otsuka beats back Novartis opposition with $15M purchase of smart pill developer Proteus |
Otsuka can now move ahead to acquire its digital pill partner and now-bankrupt Proteus Digital Health for $15 million. | Otsuka's $15 million offer to buy up now-bankrupt Proteus Digital Health has been cleared by a U.S. court despite a group of investors, including Novartis, calling the deal "nothing more than a giveaway" to an insider.
Read more
2020-08-12 (fiercehealthcare.com)
Novartis, other investors try to delay sale of Proteus Digital Health
There is a potential deal on the table for Proteus Digital Health to exit bankruptcy in a $15 million sale to Otsuka Pharmaceutical. In an 11th-hour play, a group of investors including drug giant Novartis are trying to push off that sale.
Read more
2020-08-12 (fiercehealthcare.com)
Novartis, other investors try to delay sale of Proteus Digital Health
There is a potential deal on the table for Proteus Digital Health to exit bankruptcy in a $15 million sale to Otsuka Pharmaceutical. In an 11th-hour play, a group of investors including drug giant Novartis are trying to push off that sale.
Read more